Sangamo Therapeutics: HC Wainwright Raises Buy Rating, PT Boosted to $10

Sangamo Therapeutics: HC Wainwright Raises Buy Rating, PT Boosted to $10

Richmond, California - September 2, 2025 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO) has received a positive upgrade in its stock rating by HC Wainwright, with the target price (PT) boosted to $10. The upgrade reflects the company's recent progress in its clinical trials and the potential of its gene therapy product candidate, ST-920, for the treatment of Fabry disease.

The upgrade comes on the heels of detailed data presented at the International Congress of Inborn Errors of Metabolism 2025 (ICIEM2025) in Kyoto, Japan. The STAAR study demonstrated a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients, which the U.S. Food and Drug Administration (FDA) has agreed will serve as the primary basis for approval. The study also showed a favorable safety and tolerability profile, with no serious adverse events or study discontinuations [2].

Sangamo Therapeutics is a genomic medicine company that focuses on translating scientific breakthroughs into medicines for serious diseases. The company's product candidates include ST-920, a gene therapy product candidate in Phase 1/2 clinical study for Fabry disease, and SB-525, a gene therapy product candidate in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Sangamo has strategic partnerships with leading pharmaceutical companies, including Biogen, Kite Pharma, Pfizer, and Novartis [1].

The upgrade by HC Wainwright highlights the market's optimism about Sangamo's pipeline and the potential of ST-920 as a one-time, durable treatment for Fabry disease. The company is expected to submit a Biologics License Application (BLA) in 2026 under the Accelerated Approval pathway.

References:
[1] https://finance.yahoo.com/quote/SGMO/
[2] https://www.globenewswire.com/news-release/2025/09/04/3144482/33816/en/Sangamo-Therapeutics-Presents-Detailed-Data-from-Registrational-STAAR-Study-in-Fabry-Disease-at-International-Congress-of-Inborn-Errors-of-Metabolism-2025.html